Price T Rowe Associates Inc. MD cut its holdings in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 13.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 246,447 shares of the biopharmaceutical company's stock after selling 39,852 shares during the period. Price T Rowe Associates Inc. MD's holdings in Royalty Pharma were worth $6,287,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of RPRX. Brooklyn Investment Group increased its holdings in Royalty Pharma by 1,006.9% in the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 876 shares in the last quarter. Allworth Financial LP lifted its position in Royalty Pharma by 417.6% in the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 877 shares in the last quarter. Riverview Trust Co raised its holdings in Royalty Pharma by 3,953.3% during the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 1,186 shares in the last quarter. Fifth Third Bancorp boosted its stake in Royalty Pharma by 187.1% during the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 997 shares during the period. Finally, Rakuten Securities Inc. lifted its position in shares of Royalty Pharma by 160.5% in the 4th quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 1,003 shares during the period. 54.35% of the stock is owned by institutional investors and hedge funds.
Royalty Pharma Price Performance
NASDAQ:RPRX traded up $0.11 during trading hours on Friday, hitting $33.21. 1,188,264 shares of the stock traded hands, compared to its average volume of 3,298,181. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $34.20. The company has a market cap of $19.14 billion, a price-to-earnings ratio of 22.90, a price-to-earnings-growth ratio of 2.31 and a beta of 0.49. The stock has a 50 day moving average price of $32.39 and a 200 day moving average price of $29.72. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Sell-side analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.
Royalty Pharma Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 2.65%. The ex-dividend date is Friday, May 16th. Royalty Pharma's payout ratio is 60.69%.
Wall Street Analysts Forecast Growth
Separately, Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $42.50.
View Our Latest Report on Royalty Pharma
About Royalty Pharma
(
Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Featured Articles
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
